TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24469903

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training: three sessions per week, five series of 15 seconds at 30 Hz for 6 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group with normal daily life
Number of subjects: 62
Study: 22559080

Group type: EXPERIMENTAL
Intervention: Earplugs during the night
Number of subjects: 136

Group type: COMPARATOR
Intervention: No earplugs during the night (Control)
Number of subjects: 136
Study: 20236788

Group type: EXPERIMENTAL
Intervention: Smoking cessation (verified by exhaled carbon monoxide levels)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 1504
Study: 17639302

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison between Rosiglitazone and Sulfonylurea
Number of subjects: 64
Study: 16135471

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (individualized fatigue education and support program delivered in clinic and by phone over three 10- to 20-minute sessions 1 week apart)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 109
Study: 12070620

Group type: EXPERIMENTAL
Intervention: 100%G (maximal voluntary contraction for 6 s per set, 12 sets per session)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60%G (60% of MVC for 30 s per set, 4 sets per session)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both 100%G and 60%G
Number of subjects: 12
Study: 9649710

Group type: EXPERIMENTAL
Intervention: Skin biopsies from actinic prurigo patients (UV-induced lesions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Skin biopsies from normal individuals (control)
Number of subjects: 10
Study: 7673040

Group type: EXPERIMENTAL
Intervention: Cut-out plastic mask
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Full plastic mask
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cut-out Orfit mask
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Full Orfit mask
Number of subjects: 43

Group type: COMPARATOR
Intervention: Orfit masks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cut-out masks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Full masks
Number of subjects: 43
Study: 2032263

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7362972

Group type: EXPERIMENTAL
Intervention: Hypocount
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucochek
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Eyetone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reflomat
Number of subjects: 24
Study: 31274388

Group type: EXPERIMENTAL
Intervention: oscillometric ankle-brachial index (oABI)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Doppler-based ankle-brachial index (dABI)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: pulse wave index (PWI)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Combination of oABI and PWI
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Time requirement for oABI
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Patient preference for future testing
Number of subjects: 286
Study: 28836279

Group type: EXPERIMENTAL
Intervention: Zithromax® (azithromycin)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Open flap debridement without antibiotics (control)
Number of subjects: 39
Study: 26785394

Group type: EXPERIMENTAL
Intervention: Physiotherapy and Occupational Therapy
Number of subjects: 762

Group type: COMPARATOR
Intervention: No Therapy
Number of subjects: 762
Study: 24163397

Group type: EXPERIMENTAL
Intervention: At-home assessments
Number of subjects: 57

Group type: COMPARATOR
Intervention: In-hospital assessments
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Gross Motor Function Measure
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Modified Hammersmith Functional Motor Scale
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Manual Muscle Test
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Serum biomarker
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Forced vital capacity
Number of subjects: 57
Study: 22827885

Group type: EXPERIMENTAL
Intervention: Goal-setting intervention (identification of up to five personal goals in physical activity, cognitive activity, diet and health, and social engagement)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Goal-setting with mentoring (goal-setting interview followed by bi-monthly telephone mentoring)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (an interview involving a general discussion about the center)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Goal-setting intervention
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Goal-setting with mentoring
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 19082671

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 17322803

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4% articaine and 2% lidocaine
Number of subjects: 30
Study: 15450559

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg q12h for 5 doses via suppository, followed by oral 250 mg q8h for 6 doses)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 11605926

Group type: EXPERIMENTAL
Intervention: Water-garment warming system
Number of subjects: 53

Group type: COMPARATOR
Intervention: Upper body forced-air warming system
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 9832480

Group type: EXPERIMENTAL
Intervention: PTCA in unstable angina patients with raised baseline levels of CRP, SAA, and IL-6
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Diagnostic coronary angiography in unstable angina patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: PTCA in stable angina patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: Diagnostic coronary angiography in stable angina patients
Number of subjects: 86
Study: 8166478

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with thoracic radiotherapy
Number of subjects: 2140

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2140
Study: 2189772

Group type: EXPERIMENTAL
Intervention: Private family practice with study personnel screening
Number of subjects: 576

Group type: COMPARATOR
Intervention: Academic medical practice with practice receptionist screening
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Informed consent read by study personnel
Number of subjects: 576

Group type: COMPARATOR
Intervention: Informed consent read by subjects themselves
Number of subjects: 576
Study: 383437

Group type: EXPERIMENTAL
Intervention: carmustin + 5-fluorouracil
Number of subjects: 109

Group type: COMPARATOR
Intervention: carmustin + ftorafur
Number of subjects: 109
Study: 31642586

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 411

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 411
Study: 31272568

Group type: EXPERIMENTAL
Intervention: Obese HFpEF patients
Number of subjects: 151

Group type: COMPARATOR
Intervention: Nonobese HFpEF patients
Number of subjects: 151
Study: 29016544

Group type: EXPERIMENTAL
Intervention: Topical vibration anesthesia during BTX‐A injections
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control side (BTX‐A injections only)
Number of subjects: 53
Study: 25681059

Group type: EXPERIMENTAL
Intervention: Filgotinib (GLPG0634) 10 mg to 200 mg single doses and 300 mg to 450 mg daily doses for 10 days
Number of subjects: 0
Study: 23377746

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sodium thiopental
Number of subjects: 96
Study: 20663994

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 0
Study: 19368418

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17299493

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (15 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15074398

Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Observation (watchful waiting)
Number of subjects: 137
Study: 11571763

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Galantamine 36 mg/day
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 9512200

Group type: EXPERIMENTAL
Intervention: Medi-Jector
Number of subjects: 18

Group type: COMPARATOR
Intervention: Multidose injection pen
Number of subjects: 18
Study: 8148217

Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg) and Atenolol (100 mg) co-administration
Number of subjects: 0
Study: 2659002

Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl magnesium glutamate (NAAGA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1168413

Group type: EXPERIMENTAL
Intervention: Alice strain live attenuated influenza A (H3N2) vaccine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Killed parenteral (KP) bivalent influenza vaccine
Number of subjects: 150
Study: 30340960

Group type: EXPERIMENTAL
Intervention: Early oral hydration (EOH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional oral hydration (COH)
Number of subjects: 0
Study: 29310386

Group type: EXPERIMENTAL
Intervention: High viscosity cement (group H, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low viscosity cement (group L, n = 50)
Number of subjects: 100
Study: 26039792

Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscope (3.0-mm) with EBUS, fluoroscopy, and virtual bronchoscopic navigation guidance
Number of subjects: 305

Group type: COMPARATOR
Intervention: Thin bronchoscope with guide sheath (4.0-mm)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscope (3.0-mm)
Number of subjects: 305
Study: 23213101

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² bolus followed by 2400 mg/m² 46-hour continuous infusion, once every 2 weeks)
Number of subjects: 342

Group type: COMPARATOR
Intervention: gemcitabine (1,000 mg/m² weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX and gemcitabine
Number of subjects: 342
Study: 20079597

Group type: EXPERIMENTAL
Intervention: Restraint chair
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 10
Study: 19887477

Group type: EXPERIMENTAL
Intervention: 1 mg/d anastrozole
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10 mg/wk tamoxifen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of anastrozole and tamoxifen
Number of subjects: 75

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 75
Study: 16400057

Group type: EXPERIMENTAL
Intervention: Soybean ferritin (140 microg Fe as ferritin, 2.5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: FeSO4 (140 microg Fe as FeSO4, 2.5 mg)
Number of subjects: 16
Study: 14718117

Group type: EXPERIMENTAL
Intervention: High intensity training (group A) at 70 (22) W, total work 8050 (2882) kJ
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low intensity training (group B) at 35 (10) W, total work 4044 (1205) kJ
Number of subjects: 35
Study: 11421999

Group type: EXPERIMENTAL
Intervention: Fast infusion of rilmenidine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Slow infusion of rilmenidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study: 9347381

Group type: EXPERIMENTAL
Intervention: Fluvoxamine-lithium therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluvoxamine monotherapy
Number of subjects: 12
Study: 8482046

Group type: EXPERIMENTAL
Intervention: Oral alcohol (0.5 g/kg body weight diluted to 300 ml in sugar-free orange juice)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral alcohol (0.5 g/kg body weight diluted to 300 ml in sugar-free orange juice) during head-up tilt
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo during head-up tilt
Number of subjects: 10
Study: 3087252

Group type: EXPERIMENTAL
Intervention: 200 mg of cromolyn
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg of cromolyn
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30587221

Group type: EXPERIMENTAL
Intervention: Maintain OAC treatment until the day before surgery and resume OAC treatment the day after surgery.
Number of subjects: 386

Group type: COMPARATOR
Intervention: Stop OAC treatment (with or without low-molecular-weight heparin bridging therapy) according to the anaesthesia guidelines.
Number of subjects: 386
Study: 27404058

Group type: EXPERIMENTAL
Intervention: Girls on the Go! program (10-week intervention)
Number of subjects: 122
Study: 24524222

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formoterol monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22624298

Group type: EXPERIMENTAL
Intervention: 120 mg of iron
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 120 mg of iron in refined palm oil
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 120 mg of iron in palm oil with CTCMC (two doses)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (without active supplementation)
Number of subjects: 17
Study: 20171424

Group type: EXPERIMENTAL
Intervention: S-amlodipine 5 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Amlodipine racemate 10 mg
Number of subjects: 48
Study: 18394874

Group type: EXPERIMENTAL
Intervention: Labetalol 10mg iv with midazolam-alfentanil sedation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo with midazolam-alfentanil sedation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Labetalol 10mg iv with midazolam-alfentanil sedation (in subgroup)
Number of subjects: 120
Study: 16160499

Group type: EXPERIMENTAL
Intervention: Complete MoisturePlus
Number of subjects: 31

Group type: COMPARATOR
Intervention: Opti‐Free Express
Number of subjects: 31
Study: 12521629

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Beta blockers discontinued
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Continuation of beta blockers
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Withdrawal of beta blockers
Number of subjects: 949
Study: 10807011

Group type: EXPERIMENTAL
Intervention: Hypertonic hydroxyethyl starch (HES 6%; 7.2% NaCl)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isotonic hydroxyethyl starch (HES 6%; 0.9% NaCl)
Number of subjects: 32
Study: 8872324

Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 i.v. (VAC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Mitoxantrone 10 mg/m2 (VNC)
Number of subjects: 110
Study: 1514333

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6711601

Group type: EXPERIMENTAL
Intervention: Folic acid therapy
Number of subjects: 2
Study: 31425780

Group type: EXPERIMENTAL
Intervention: 0.25% delgocitinib ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% delgocitinib ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 0
Study: 30368336

Group type: EXPERIMENTAL
Intervention: Diaphragmatic myofascial release techniques
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo techniques
Number of subjects: 75
Study: 26795209

Group type: EXPERIMENTAL
Intervention: CT-P13 (5 mg/kg)
Number of subjects: 250

Group type: COMPARATOR
Intervention: RP (5 mg/kg)
Number of subjects: 250
Study: 24556513

Group type: EXPERIMENTAL
Intervention: ILMA-Fastrach™
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: air-Q(®)
Number of subjects: 80
Study: 22729307

Group type: EXPERIMENTAL
Intervention: Subxyphoid pleural drain
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intercostal pleural drain
Number of subjects: 40
Study: 19889249

Group type: EXPERIMENTAL
Intervention: Diet A (40% carbohydrate, 30% protein, 30% fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diet B (55% carbohydrate, 15% protein, 30% fat)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both diets (A and B)
Number of subjects: 36
Study: 16877461

Group type: EXPERIMENTAL
Intervention: New footwear design (intervention group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional footwear design (control group)
Number of subjects: 80
Study: 15875154

Group type: EXPERIMENTAL
Intervention: Simvastatin 10, 20, 40 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12519867

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg every 8 h, orally, for 7 d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10657829

Group type: EXPERIMENTAL
Intervention: Transfusion guidelines modified in April 1989, September 1991, and January 1995
Number of subjects: 256
Study: 8882210

Group type: EXPERIMENTAL
Intervention: 6% NaCl (HS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.9% NaCl (IS)
Number of subjects: 52
Study: 1677012

Group type: EXPERIMENTAL
Intervention: Cetirizine therapy
Number of subjects: 14
Study: 6626483

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy + medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 0
Study: 31928076

Group type: EXPERIMENTAL
Intervention: NT-proBNP (N-terminal Pro-B-type natriuretic peptide)
Number of subjects: 4147

Group type: EXPERIMENTAL
Intervention: uPA (urokinase-type plasminogen activator)
Number of subjects: 4147

Group type: EXPERIMENTAL
Intervention: ADM (adrenomedullin)
Number of subjects: 4147

Group type: EXPERIMENTAL
Intervention: IL (interleukin) 16
Number of subjects: 4147

Group type: EXPERIMENTAL
Intervention: cFn (cellular fibronectin)
Number of subjects: 4147

Group type: EXPERIMENTAL
Intervention: IGFBP3 (insulin-like growth factor-binding protein 3)
Number of subjects: 4147
Study: 30594347

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (3 sessions per week for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home-based exercise training and Usual care
Number of subjects: 40
Study: 28397334

Group type: EXPERIMENTAL
Intervention: Nurse-led education intervention
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Nurse-led education plus ACT intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 118
Study: 26978049

Group type: EXPERIMENTAL
Intervention: Tenoten children (1 tablet 3 times a day for 12 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 24199581

Group type: EXPERIMENTAL
Intervention: Liver-soothing and blood-activating decoction combined with acupuncture
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride
Number of subjects: 63
Study: 21095141

Group type: EXPERIMENTAL
Intervention: Colour-Doppler ultrasound (CDUS)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (CTA)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (MRA)
Number of subjects: 108
Study: 18946662

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 32
Study: 17689326

Group type: EXPERIMENTAL
Intervention: Potential interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plausible interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efficacious interventions
Number of subjects: 0
Study: 14751003

Group type: EXPERIMENTAL
Intervention: levodopa (n = 16)
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo (n = 24)
Number of subjects: 39
Study: 11387585

Group type: EXPERIMENTAL
Intervention: Bon Saint Côme device (DG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional neurorehabilitation (CG)
Number of subjects: 20
Study: 9463203

Group type: EXPERIMENTAL
Intervention: 5 ml of 2% mepivacaine and 1 ml (30 mg) of ketorolac
Number of subjects: 72

Group type: COMPARATOR
Intervention: 5 ml of 2% mepivacaine and 1 ml of saline solution
Number of subjects: 72

Group type: COMPARATOR
Intervention: 5 ml of 2% mepivacaine and 1 ml of saline solution plus 30 mg of ketorolac intravenously
Number of subjects: 72
Study: 8485325

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Injection sclerotherapy of esophageal varices (Control)
Number of subjects: 10
Study: 3446537

Group type: EXPERIMENTAL
Intervention: Day case strabismus surgery without post-operative topical medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overnight stay with topical antibiotic and anti-inflammatory therapy for 14 days
Number of subjects: 0
Study: 30630783

Group type: EXPERIMENTAL
Intervention: Recombinant human endo‐statin combined with carboplatin and etoposide (CE regimen)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Carboplatin and etoposide
Number of subjects: 72